From Justin · PEDs & Compounds
Liraglutide monograph
Justin Harris — IFBB Pro Coach
From Justin
Liraglutide is a solid appetite suppression tool, but it's not magic. It's a GLP-1 receptor agonist that slows gastric emptying and reduces hunger signals — basically makes it easier to stick to a calorie deficit by killing food drive.
The mechanism is straightforward: it mimics incretin hormones that tell your brain you're full and slow down how fast food leaves your stomach. Weight loss comes from eating less, not from any direct fat-burning effect — but it can come at the expense of muscle mass if proper nutrition and weight training aren't utilized.
Overview
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used clinically for type 2 diabetes and chronic weight management. It lowers glucose in a glucose-dependent way, slows gastric emptying, and reduces appetite/food intake, which is why it is relevant to obesity and body-composition coaching. It is not a performance enhancer in the anabolic sense, and the main body-composition effect is appetite suppression and calorie reduction, not direct fat oxidation or muscle gain.[^1]
Pharmacokinetics & Mechanism
- Class: GLP-1 receptor agonist; acylated human incretin analog peptide
- Mechanism of action: Liraglutide binds to and activates the GLP-1 receptor. In humans it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and increases satiety while reducing hunger and prospective food intake. Weight loss is driven mainly by reduced energy intake rather than increased energy expenditure.
- Target(s): Primary target: GLP-1 receptor (GLP-1R). Downstream physiologic effects include pancreatic beta-cell insulin secretion, alpha-cell glucagon suppression, central appetite/satiety pathways, and delayed gastric emptying via gut-brain signaling. No androgenic, mTOR, or catecholamine-driven performance pathway target is established.
- Route(s) of administration: Subcutaneous injection only. Given once daily in abdomen, thigh, or upper arm. Not for IV or IM use.
- Onset: Clinical effects on appetite and gastric slowing can begin with early dosing, but full weight-loss response is gradual over weeks as dose is titrated. Peak plasma concentration occurs at about 11 hours after subcutaneous dosing.
- Half-life: Approximately 13 hours in labeling/EMA pharmacokinetics, which supports once-daily dosing. I did not find a credible source indicating a long-acting depot or DAC/extended variant for liraglutide itself; that kind of extended design is not part of standard liraglutide.
- Metabolism / clearance: Endogenously metabolized like a large peptide/protein rather than by a single dominant organ. Intact liraglutide is not detected in urine or feces after radiolabeled dosing; minor metabolites are excreted in urine and feces. Mean clearance after subcutaneous administration is about 0.9 to 1.4 L/h.
Members from here
The opener is free so Google can find us. The rest is how Justin actually uses it. That is the $29.99.
5 more minutes of this lecture, the full Troponin University library, and the TroponinIQ coach built on the same reasoning — one membership.
Up next